Ozempic Titration: What Changes at Each Dose

Written by the GLP-1 Coach editorial team. Last updated August 12, 2026.

"Ozempic dose" has been quietly climbing as a search query even as most other Ozempic-related searches have leveled off — which tracks with what people actually run into a few weeks into treatment. The starter dose isn't the therapeutic one, dose increases don't feel like nothing, and the details of when and why the dose changes aren't always spelled out clearly by the prescriber.

Here's the actual FDA-labeled titration schedule for semaglutide, what tends to shift at each step, and — because it's the part of the equation this site keeps circling back to — how dose changes connect to the protein and muscle-preservation side of GLP-1 therapy.

What is the standard Ozempic titration schedule?

Ozempic (semaglutide, approved for type 2 diabetes) follows a stepped weekly-injection schedule, with each step held for at least 4 weeks before moving up:

Step	Dose	Duration	Notes
1	0.25 mg weekly	Weeks 1–4	Starter dose; not considered therapeutic
2	0.5 mg weekly	Weeks 5–8 (or longer)	First maintenance dose; some stay here long-term
3	1 mg weekly	Weeks 9+ (if needed)	Most common long-term maintenance dose
4	2 mg weekly	After ≥4 weeks at 1 mg (if needed)	Current maximum on the label

Wegovy (also semaglutide, but approved for weight management) uses the same molecule but a more aggressive schedule that peaks at 2.4 mg weekly, stepping through 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over roughly 16–20 weeks. That's the same drug at a higher target dose, which is worth knowing if you're comparing your experience with someone on the other label.

What actually changes at each dose increase?

The most common pattern is a short return of the side effects you had at the start — nausea, early fullness, sometimes fatigue — for a few days to a couple of weeks after the increase, before things settle again. This is why the label mandates a minimum of 4 weeks between steps: not because the drug needs that long to work, but because your GI system needs the runway to adjust. For a head-to-head view of how the side effect profiles compare across semaglutide and tirzepatide medications at each stage, see Ozempic vs Wegovy vs Mounjaro: side effects compared.

In practice, dose-increase weeks are often when people second-guess whether the medication is still tolerable, because they've forgotten what week 1–2 felt like. Treating each increase like a mini-restart (smaller meals, protein-first, low-fat food, staying upright after eating) tends to shorten the rough window meaningfully.

Appetite suppression usually gets stronger with each step up. That's the intended effect — it's why higher doses produce more weight loss on average — but it also means the practical problem of how to eat enough of what matters gets harder in parallel with the dose curve.

Why does the protein problem get worse at higher doses?

This is the piece that doesn't get talked about enough in dose-tier explainers.

At 0.25 mg, most people can still eat close to their usual quantity and variety. At 1 mg or 2 mg, appetite suppression is often meaningful enough that total daily food intake can drop 30–50% or more — and protein, being harder to eat when nothing sounds appealing, is usually the first macro to fall. This protein gap is one of the most common drivers of weight-loss plateaus that look like medication failure but are actually a muscle-metabolic issue.

The consequence is quiet: if you're losing weight steadily on 1 mg but only getting 50 g of protein a day for weeks at a stretch, a significant portion of that weight loss can come from lean tissue rather than fat. You won't feel it happening. The scale will keep going down. But the body composition of what you're losing is very different than it would be at 90–100 g of protein daily, and that difference matters most later — during dose plateaus, on maintenance, and after eventually stopping.

The practical version: as your dose goes up, your protein target doesn't. It stays where it needs to be for muscle preservation, but hitting it gets harder. That's the mismatch worth naming out loud, because it's what makes tracking (rather than guessing) more useful at higher doses than at lower ones.

Do injection sites matter more at higher doses?

A common assumption is that higher doses mean bigger injection volumes and therefore more need for site rotation. That's not quite how the Ozempic pens work — Novo Nordisk uses different concentrations for the 0.25/0.5 mg, 1 mg, and 2 mg pens, so the actual injection volume per dose stays roughly the same across strengths (all around 0.5–0.75 mL, depending on the pen).

Rotation still matters — repeated injections in the same spot can cause lipodystrophy (lumps or hardened tissue under the skin) that can affect absorption — but the driver is repetition, not dose size. The three FDA-recognized sites are the abdomen (avoiding a ~2-inch radius around the navel), the front or outer thigh, and the back of the upper arm. Rotating weekly across sites is the standard recommendation regardless of what dose you're on.

How does Mounjaro's dosing compare to Ozempic?

Since "ozempic mounjaro" is a common paired search: Mounjaro (tirzepatide) uses a similar 4-week-per-step titration but a wider dose range.

Medication	Starter dose	Escalation steps	Maintenance options	Max dose
Ozempic (semaglutide)	0.25 mg	0.5 → 1 → 2 mg	0.5, 1, 2 mg	2 mg weekly
Mounjaro (tirzepatide)	2.5 mg	5 → 7.5 → 10 → 12.5 → 15 mg	5, 10, 15 mg	15 mg weekly

For Mounjaro, the 2.5, 7.5, and 12.5 mg steps are titration transitions, not typical long-term destinations.

The practical patterns are similar: each step-up tends to bring a fresh side-effect window, appetite suppression scales with dose, and the protein problem intensifies at higher doses on tirzepatide the same way it does on semaglutide. The main difference is the ceiling — 15 mg tirzepatide produces stronger appetite suppression than 2 mg semaglutide for many people, which is part of why Mounjaro/Zepbound trials have generally shown larger average weight loss.

What's worth tracking around dose changes?

If you have any kind of tracking habit — even a rough one — dose-change weeks are the highest-value week to actually look at your data:

• Nausea pattern: is it settling within 5–10 days, or lingering past two weeks? Lingering may be worth a prescriber conversation.
• Protein average: dose increases are the point protein most often drops without you noticing.
• Weight trend: expect noise for 1–2 weeks post-increase; the trend line matters more than any single number.

The point isn't perfectionism — it's that dose-change weeks are the ones where "how am I actually doing" is hardest to answer from memory, and easiest to answer from a quick glance at a chart.

The bottom line

Bottom line: Ozempic titration is 0.25 → 0.5 → 1 → 2 mg, with at least 4 weeks per step. Each increase usually brings a fresh nausea window and stronger appetite suppression, which means protein intake is the hardest to maintain right at the point it matters most. Treat every step-up like a mini-restart, and watch protein averages more carefully than the scale.

Final Thoughts

The right dose for you depends on what you're optimizing for. If glycemic control is your primary goal and you're tolerating a lower dose well, staying at 0.5 or 1 mg long-term is a completely reasonable outcome — not everyone needs to reach the top of the schedule. If weight loss is the main driver, higher doses (or the Wegovy label) typically produce more of it, at the cost of more aggressive appetite suppression and a harder protein-intake problem.

What holds across every dose: the medication does the appetite work; you still have to do the protein work. Dose changes are the moments where that becomes hardest, which is exactly why they're the highest-value moments to actually look at your tracking data. This site's tools are built for that kind of week-over-week visibility — but the dose itself, and any decision to move up, down, or stay, belongs firmly in the prescriber conversation.

---

Related:

• Ozempic vs Wegovy vs Mounjaro: Side Effects Compared Week by Week
• Is Your Weight-Loss Plateau Actually Muscle Loss in Disguise?
• Muscle Loss After Stopping GLP-1s: Why You Likely Regain Fat, Not Muscle

---

This article is educational and not a substitute for medical advice. Dose changes, titration timing, and staying at a specific dose long-term are decisions for your prescriber based on your individual response and goals.

Sources: Ozempic prescribing information, Novo Nordisk; Wegovy dosing schedule, Novo Nordisk; Mounjaro dosing guide, GoodRx; Ozempic pen concentrations & volumes, Medscape.